Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers

Next Previous
Trial Profile

A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion (Primary) ; Remogliflozin etabonate (Primary)
  • Indications Depressive disorders; Obesity; Seasonal affective disorder; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 21 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top